Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir -based triple therapy is useful for predicting virological response.

Trial Profile

Therapeutic drug monitoring of telaprevir in chronic hepatitis C patients receiving telaprevir -based triple therapy is useful for predicting virological response.

Completed
Phase of Trial: Phase I

Latest Information Update: 03 Oct 2013

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
  • Indications Hepatitis C
  • Focus Pharmacokinetics
  • Most Recent Events

    • 22 Jan 2013 The UMIN record reported the study results although it was stated the results are unpublished.
    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top